<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36951167</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0962</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Lupus</Title><ISOAbbreviation>Lupus</ISOAbbreviation></Journal><ArticleTitle>Hospitalized patients with positive antiphospholipid antibodies who have low complement levels are at increased risk for death-a retrospective cohort study.</ArticleTitle><Pagination><StartPage>668</StartPage><EndPage>674</EndPage><MedlinePgn>668-674</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/09612033231164091</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To investigate whether low complement levels can predict worse outcomes in patients hospitalized with positive anti-phospholipid antibodies.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a retrospective cohort study. We obtained demographics, laboratory, and prognostic data of all consecutive patients hospitalized between 2007 and 2021, for whatever reason, with at least one positively abnormal anti-phospholipid antibody, who were also tested for complement levels (C3 or C4). We then compared the rates of long-term mortality, 1-year mortality, deep vein thrombosis, and pulmonary emboli between groups of low complement and normal complement levels. Multivariate analysis was used to control for levels of clinical and laboratory confounders.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified 32,286 patients tested for anti-phospholipid antibodies. Of those patients, 6800 tested positive for at least one anti-phospholipid antibody and had a documented complement level. Significant higher mortality rates were found in the low complement group, with an odds ratio for mortality (OR 1.93 CI 1.63-2.27 <i>p</i> &lt; .001). Deep vein thrombosis and pulmonary emboli rates were similar. Multivariate analysis confirmed that low complement was an independent predictor for mortality after controlling for age, sex, dyslipidemia, chronic heart failure (CHF), chronic kidney disease (CKD), and anemia.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study results indicate that low complement is associated with significantly higher mortality rates in admitted patients with elevated levels of anti-phospholipid antibodies. This finding correlates with recent literature suggesting a vital role for complement activation in anti-phospholipid syndrome.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Itelman</LastName><ForeName>Edward</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-0142-0253</Identifier><AffiliationInfo><Affiliation>Internal Medicine "T", Chaim Sheba Medical Center, Tel Hashomer, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler Faculty of Medicine, Tel Aviv University, Tel Hashomer, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perelman</LastName><ForeName>Maxim</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Internal Medicine "T", Chaim Sheba Medical Center, Tel Hashomer, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler Faculty of Medicine, Tel Aviv University, Tel Hashomer, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bivar</LastName><ForeName>Natali</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Internal Medicine "T", Chaim Sheba Medical Center, Tel Hashomer, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler Faculty of Medicine, Tel Aviv University, Tel Hashomer, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kent</LastName><ForeName>Daniella</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Internal Medicine "T", Chaim Sheba Medical Center, Tel Hashomer, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler Faculty of Medicine, Tel Aviv University, Tel Hashomer, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vaisman</LastName><ForeName>Adva</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Internal Medicine "T", Chaim Sheba Medical Center, Tel Hashomer, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler Faculty of Medicine, Tel Aviv University, Tel Hashomer, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Segal</LastName><ForeName>Gad</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Internal Medicine "T", Chaim Sheba Medical Center, Tel Hashomer, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler Faculty of Medicine, Tel Aviv University, Tel Hashomer, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Negru</LastName><ForeName>Liat</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Internal Medicine "T", Chaim Sheba Medical Center, Tel Hashomer, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler Faculty of Medicine, Tel Aviv University, Tel Hashomer, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dagan</LastName><ForeName>Amir</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Internal Medicine "T", Chaim Sheba Medical Center, Tel Hashomer, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler Faculty of Medicine, Tel Aviv University, Tel Hashomer, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus</MedlineTA><NlmUniqueID>9204265</NlmUniqueID><ISSNLinking>0961-2033</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017152">Antibodies, Antiphospholipid</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-36-7</RegistryNumber><NameOfSubstance UI="D003165">Complement System Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017152" MajorTopicYN="N">Antibodies, Antiphospholipid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016736" MajorTopicYN="Y">Antiphospholipid Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003165" MajorTopicYN="N">Complement System Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="Y">Venous Thrombosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">anti-phospholipid antibodies</Keyword><Keyword MajorTopicYN="N">complement</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">thrombosis</Keyword></KeywordList><CoiStatement>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. The author(s) received no financial support for the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>23</Day><Hour>5</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36951167</ArticleId><ArticleId IdType="pmc">PMC10155279</ArticleId><ArticleId IdType="doi">10.1177/09612033231164091</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mehrani T, Petri M. Handbook of systemic autoimmune diseases. In: Anti-Phospholipid Syndrome in Systemic Autoimmune Diseases, Vol 10. Elsevier, 2009, pp. 13&#x2013;34. DOI: 10.1016/S1571-5078(08)00402-9.Chapter 2 epidemiology of the anti-phospholipid syndrome.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1571-5078(08)00402-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M. Epidemiology of the anti-phospholipid antibody syndrome. J Autoimmun 2000; 15(2): 145&#x2013;151. DOI: 10.1006/jaut.2000.0409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jaut.2000.0409</ArticleId><ArticleId IdType="pubmed">10968901</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel-Wahab N, Talathi S, Lopez-Olivo MA, et al.Risk of developing anti-phospholipid antibodies following viral infection: a systematic review and meta-analysis. Lupus 2018; 27(4): 572&#x2013;583. DOI: 10.1177/0961203317731532.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203317731532</ArticleId><ArticleId IdType="pubmed">28945149</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervera R, Asherson RA, Acevedo ML, et al.Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients. Ann Rheum Dis 2004; 63(10): 1312&#x2013;1317. DOI: 10.1136/ard.2003.014175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2003.014175</ArticleId><ArticleId IdType="pmc">PMC1754783</ArticleId><ArticleId IdType="pubmed">15361392</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel-Wahab N, Tayar JH, Fa'ak F, et al.Systematic review of observational studies reporting anti-phospholipid antibodies in patients with solid tumors. Blood Adv 2020; 4(8): 1746&#x2013;1755. DOI: 10.1182/bloodadvances.2020001557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2020001557</ArticleId><ArticleId IdType="pmc">PMC7189282</ArticleId><ArticleId IdType="pubmed">32337583</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaturvedi S, Brodsky RA, McCrae KR. Complement in the pathophysiology of the anti-phospholipid syndrome. Front Immunol 2019; 10: 449. DOI: 10.3389/fimmu.2019.00449.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00449</ArticleId><ArticleId IdType="pmc">PMC6426753</ArticleId><ArticleId IdType="pubmed">30923524</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu C, Gao L, Xie W, et al.Beta2-glycoprotein i is a cofactor for tissue plasminogen activator-mediated plasminogen activation. Arthritis Rheum 2009; 60(2): 559&#x2013;568. DOI: 10.1002/art.24262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24262</ArticleId><ArticleId IdType="pmc">PMC2965030</ArticleId><ArticleId IdType="pubmed">19180513</ArticleId></ArticleIdList></Reference><Reference><Citation>Runjic F, Martinovic-Kaliterna D, Salamunic I, et al.Association of anti-cardiolipin antibodies, complement and leptin with the severity of coronary artery disease expressed as syntax score. J Physiol Pharmacol 2020; 71(3). DOI: 10.26402/jpp.2020.3.09.</Citation><ArticleIdList><ArticleId IdType="doi">10.26402/jpp.2020.3.09</ArticleId><ArticleId IdType="pubmed">33077690</ArticleId></ArticleIdList></Reference><Reference><Citation>Urbanus RT, de Laat B. Antiphospholipid antibodies and the protein C pathway. Lupus 2010; 19(4): 394&#x2013;399. DOI: 10.1177/0961203309360841.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203309360841</ArticleId><ArticleId IdType="pubmed">20353976</ArticleId></ArticleIdList></Reference><Reference><Citation>Tedesco F, Borghi MO, Gerosa M, et al.Pathogenic role of complement in anti-phospholipid syndrome and therapeutic implications. Front Immunol 2018; 9: 1388. DOI: 10.3389/fimmu.2018.01388.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01388</ArticleId><ArticleId IdType="pmc">PMC6018396</ArticleId><ArticleId IdType="pubmed">29971066</ArticleId></ArticleIdList></Reference><Reference><Citation>Oku K, Nakamura H, Kono M, et al.Complement and thrombosis in the anti-phospholipid syndrome. Autoimmun Rev 2016; 15(10): 1001&#x2013;1004. DOI: 10.1016/j.autrev.2016.07.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2016.07.020</ArticleId><ArticleId IdType="pubmed">27485012</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmon JE, Girardi G, Holers VM. Complement activation as a mediator of anti-phospholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis 2002; 61(Suppl 2): ii46&#x2013;50. DOI: 10.1136/ard.61.suppl_2.ii46.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.61.suppl_2.ii46</ArticleId><ArticleId IdType="pmc">PMC1766708</ArticleId><ArticleId IdType="pubmed">12379621</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaturvedi S, Braunstein EM, Yuan X, et al.Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood 2020; 135(4): 239&#x2013;251. DOI: 10.1182/blood.2019003863.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2019003863</ArticleId><ArticleId IdType="pmc">PMC6978159</ArticleId><ArticleId IdType="pubmed">31812994</ArticleId></ArticleIdList></Reference><Reference><Citation>Breen KA, Seed P, Parmar K, et al.Complement activation in patients with isolated anti-phospholipid antibodies or primary anti-phospholipid syndrome. Thromb Haemost 2012; 107(3): 423&#x2013;429. DOI: 10.1160/TH11-08-0554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH11-08-0554</ArticleId><ArticleId IdType="pubmed">22234447</ArticleId></ArticleIdList></Reference><Reference><Citation>Tinti MG, Carnevale V, Inglese M, et al.Eculizumab in refractory catastrophic anti-phospholipid syndrome: a case report and systematic review of the literature. Clin Exp Med 2019; 19(3): 281&#x2013;288. DOI: 10.1007/s10238-019-00565-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-019-00565-8</ArticleId><ArticleId IdType="pubmed">31214910</ArticleId></ArticleIdList></Reference><Reference><Citation>Zikos TA, Sokolove J, Ahuja N, et al.Eculizumab induces sustained remission in a patient with refractory primary catastrophic anti-phospholipid syndrome. J Clin Rheumatol 2015; 21(6): 311&#x2013;313. DOI: 10.1097/RHU.0000000000000290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RHU.0000000000000290</ArticleId><ArticleId IdType="pubmed">26267719</ArticleId></ArticleIdList></Reference><Reference><Citation>Lakos G, Favaloro EJ, Harris EN, et al.International consensus guidelines on anti-cardiolipin and anti-&#x3b2;2-glycoprotein I testing: report from the 13th International Congress on Antiphospholipid Antibodies. Arthritis Rheum 2012; 64(1): 1&#x2013;10. DOI: 10.1002/art.33349.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.33349</ArticleId><ArticleId IdType="pubmed">21953634</ArticleId></ArticleIdList></Reference><Reference><Citation>Pengo V, Tripodi A, Reber G, et al.Update of the guidelines for lupus anticoagulant detection. Subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientific and standardisation committee of the international society on thrombosis and Haemostasis. J Thromb Haemost 2009; 7(10): 1737&#x2013;1740. DOI: 10.1111/j.1538-7836.2009.03555.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2009.03555.x</ArticleId><ArticleId IdType="pubmed">19624461</ArticleId></ArticleIdList></Reference><Reference><Citation>Devreese KMJ, de Groot PG, de Laat B, et al.Guidance from the Scientific and Standardization Committee for lupus anticoagulant/anti-phospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost 2020; 18(11): 2828&#x2013;2839. DOI: 10.1111/jth.15047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15047</ArticleId><ArticleId IdType="pubmed">33462974</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo-Mart&#xed;nez D, Torres Z, Amezcua-Guerra LM, et al.Are anti-phospholipid antibodies just a common epiphenomenon or are they causative of immune-mediated coagulopathy in COVID-19? Clin Rheumatol 2021; 40(7): 3015&#x2013;3019. DOI: 10.1007/s10067-021-05724-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-021-05724-5</ArticleId><ArticleId IdType="pmc">PMC8024929</ArticleId><ArticleId IdType="pubmed">33826045</ArticleId></ArticleIdList></Reference><Reference><Citation>Merashli M, Alves JD, Gentile F, et al.Relevance of anti-phospholipid antibodies in multiple sclerosis: a systematic review and meta analysis. Semin Arthritis Rheum 2017; 46(6): 810&#x2013;818. DOI: 10.1016/j.semarthrit.2016.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2016.09.010</ArticleId><ArticleId IdType="pubmed">27908533</ArticleId></ArticleIdList></Reference><Reference><Citation>Ankri A, Bonmarchand M, Coutellier A, et al.Antiphospholipid antibodies are an epiphenomenon in HIV-infected patients. AIDS 1999; 13(10): 1282&#x2013;1283. DOI: 10.1097/00002030-199907090-00024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002030-199907090-00024</ArticleId><ArticleId IdType="pubmed">10416539</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavoni V, Gianesello L, Horton A. Antiphospholipid antibodies in critically ill COVID-19 patients with thromboembolism: cause of disease or epiphenomenon? J Thromb Thrombolysis 2021. DOI: 10.1007/s11239-021-02470-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-021-02470-y</ArticleId><ArticleId IdType="pmc">PMC8109223</ArticleId><ArticleId IdType="pubmed">33973157</ArticleId></ArticleIdList></Reference><Reference><Citation>da Silva Saraiva S, de Moraes Mazetto B, Quinteiro Tobaldine L, et al.The impact of antibody profile in thrombosis associated with primary anti-phospholipid syndrome. Am J Hematol 2017; 92(11): 1163&#x2013;1169. DOI: 10.1002/ajh.24875.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.24875</ArticleId><ArticleId IdType="pubmed">28762539</ArticleId></ArticleIdList></Reference><Reference><Citation>Svenungsson E, Antovic A. The anti-phospholipid syndrome - often overlooked cause of vascular occlusions? J Intern Med 2020; 287(4): 349&#x2013;372. DOI: 10.1111/joim.13022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13022</ArticleId><ArticleId IdType="pubmed">31957081</ArticleId></ArticleIdList></Reference><Reference><Citation>De Carolis S, Botta A, Santucci S, et al.Complementemia and obstetric outcome in pregnancy with anti-phospholipid syndrome. Lupus 2012; 21(7): 776&#x2013;778. DOI: 10.1177/0961203312444172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203312444172</ArticleId><ArticleId IdType="pubmed">22635230</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>